YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP. September 29, 2022 yisheng 2022 • Transaction values YS Biopharma at pre-money equity value of $834 million • Certain investors (“Forward Purchase Investors”) are expected to invest $30 million in a private placement concurrently... Continue Reading